Pancreatic Cancer Research

ResearcherSelçuk UniversityActive in the last 2 years

Dudu Erkoç Kaya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0114-6602; OpenAlex author ID A5088484092. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 4

  1. Juglone-ascorbate treatment enhances reactive oxygen species mediated mitochondrial apoptosis in pancreatic cancer. Co-author DOI 10.1007/s11033-024-09254-6↗
  2. The effects of Juglone-Selenium combination on invasion and metastasis in pancreatic cancer cell lines. Co-author DOI 10.4314/ahs.v22i2.37↗
  3. Juglone can inhibit angiogenesis and metastasis in pancreatic cancer cells by targeting Wnt/β-catenin signaling. First author DOI 10.4149/bll_2021_020↗
  4. Investigation of juglone effects on metastasis and angiogenesis in pancreatic cancer cells. Last author DOI 10.1016/j.gene.2016.05.001↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hilal Arıkoğlu · 4 shared papers, 2016–2024 · strength 0.82
  2. Duygu Dursunoğlu · 2 shared papers, 2022–2024 · strength 0.50
  3. Ebru Avcı · 2 shared papers, 2016–2022 · strength 0.32
  4. Ebru Güçlü · 1 shared paper, 2024 · strength 0.28
  5. Esma Menevşe · 1 shared paper, 2024 · strength 0.28
  6. Fatma Göktürk · 1 shared paper, 2021 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.